Figure 6. Silencing signaling pathways in mantle cell lymphoma (MCL)-derived cells. A: Western blot analyses show the changes in protein levels. Cells were treated with the indicated concentrations of lenalidomide (Len) for 24 h. B: MTT analysis shows cell proliferation was only modestly reduced in KPUM-YY1 and MINO cells on treatment with lenalidomide for 72 h. C: MTT analysis shows cell proliferation was moderately suppressed in KPUM-YY1 and MINO cells in a dose-dependent manner by ibrutinib (Ibr) for 72 h with concurrent treatment with lenalidomide. The additive effect of lenalidomide was observed in these two cell lines.